Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Biobot Analytics

Explore full profile

Analyzes city sewage to estimate opioid consumption

Cambridge, United StatesFounded 2017Health Tech & Medtech
Valuation $100–250M Last recorded · 2024
Revenue $10–50M Latest reported FY
Headcount <100 Current team size
Total funding $50–100M Disclosed equity funding
Unlock exact values This page shows ranges. Dealroom has the exact numbers for Biobot Analytics and the history behind them.

About Biobot Analytics

Biobot Analytics is a pioneering startup specializing in wastewater epidemiology, a field that analyzes sewage to gather public health data. The company serves a diverse range of clients, including governments, businesses, universities, and health systems. By analyzing wastewater, Biobot provides critical insights into community health trends, such as the prevalence of high-risk substances, respiratory illnesses, and foodborne diseases. This information helps clients make informed decisions to improve public health efforts and enhance community well-being.

Operating in the public health and environmental monitoring market, Biobot has positioned itself as a leader in wastewater analysis. The company’s business model revolves around offering data analysis services and insights derived from wastewater samples. Clients subscribe to Biobot’s services to receive regular reports and real-time data, which they use to track and respond to health trends within their communities.

Biobot makes money through subscription fees and service contracts with its clients. Governments and enterprises pay for ongoing monitoring and analysis, while universities and health systems might engage Biobot for specific research projects or public health initiatives. The company’s innovative approach has proven especially valuable during the COVID-19 pandemic, where wastewater analysis has been used to track the spread of the virus and inform public health responses.

In summary, Biobot Analytics transforms wastewater infrastructure into a tool for public health surveillance, providing actionable insights to a wide range of clients. By leveraging this unique data source, the company helps improve health outcomes and equity in community health.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2017
Headquarters
Cambridge, United States
Employees
29
Open positions
None listed
Dealroom signal
72.7/100
Industry
Health
Sub-industry
Medical Devices
Sector
Health Tech & Medtech, Water Quality, Spinout, Urban Tech, Wastewater Treatment, Govtech and Civictech, Water Tech, YC W18, DT and LS
Technology
Hardware, Deep Tech
Business model
Marketplace & ecommerce
Client focus
b2b

Funding history

10 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
EARLY VCOther financing Jun 2025 $0 — Hyperplane VC · Atreides Management · Valor Equity Partners ↗
EARLY VCOther financing Sep 2024 $30M $120M Undisclosed ↗
Showing the latest 2 of 10 recorded eventsBook a demo for the full funding history →

Financials

Revenue over time

Revenue, earnings and other financial measures where available. Years marked “E” are estimates.

YearRevenueGrowth
2026
2025
2024
2023
2022
2021
2020 —
Company filings, research estimates and Dealroom dataBook a demo for the full financial model →

Growth signals

Biobot Analytics website traffic

Latest recorded traffic for Biobot Analytics is 5.4K monthly website visits, up 0% over the last three months. Biobot Analytics's team grew 3.6% over the past year.

Latest monthly visits5.4K 3-month web change0% 1-year team growth+3.6%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Investors

16 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed6 investors entered at this stage

  • MIT Founders' Skills Accelerator
  • Forward Deployed VC
  • Y Combinator
  • Ekistic Ventures
  • DCVC
  • The Engine

Series A8 investors entered at this stage

  • Thursday Ventures
  • Anne Wojcicki
  • Plum Alley
  • Tom Knight
  • American Family Institute
  • Valor Equity Partners
  • Hyperplane VC
  • Atreides Management

Other known investors2 additional known investors

  • Half Court VC
  • Massachusetts Institute of Technology
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Biobot Analytics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Biobot Analytics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.